Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed cardiologists indicate that a therapy's effect on the prevention of venous thromboembolism (VTE) is the attribute that most influences their prescribing decisions for VTE prophylaxis in medically ill patients. Clinical data and the opinions of interviewed thought leaders indicate that Bayer/Johnson & Johnson's Xarelto has advantages in this attribute over Sanofi-Aventis's Lovenox, the sales-leading agent in the market.

The new report entitled Venous Thromboembolism Prophylaxis in Medically Ill Patients: Significant Opportunity Awaits Therapies Offering Improved Efficacy finds that an orally available therapy for VTE prophylaxis in medically ill patients would earn a 65 percent patient share in the United States and an 80 percent patient share in Europe, according to surveyed U.S. and European cardiologists.

In 2008, Decision Resources' proprietary clinical gold standard for VTE prophylaxis in medically ill patients was GlaxoSmithKline's Arixtra, owing largely to its efficacy. Based on available data and expert opinion, Xarelto will earn gold standard status for VTE prophylaxis in medically ill patients in 2012, following its approval for the indication in 2011.

"Xarelto has competitive advantages over Arixtra in terms of delivery and safety," said Decision Resources Analyst Christine Helliwell, Ph.D. "Xarelto's main advantage is that it causes a level of bleeding similar to that of Lovenox, whereas Arixtra suffers from a perception that it causes increased rates of bleeding over Lovenox."

About the Report

Venous Thromboembolism Prophylaxis in Medically Ill Patients: Significant Opportunity Awaits Therapies Offering Improved Efficacy is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Decision Resources                      Decision Resources, Inc.   Christopher Comfort                     Elizabeth Marshall   781-296-2597                            781-296-2563   ccomfort@dresources.com                 emarshall@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

CONTACT: Christopher Comfort of Decision Resources, +1-781-296-2597,
ccomfort@dresources.com, or Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com

In Texas, Favorable Regulations for Physicians May Backfire in Light of Market Downturn

View Now